

2019-Novel Coronavirus (2019-nCoV) Triplex RT-qPCR Detection Kit Instruction for Use (Version 2.0)

PRODUCT NAME

2019-Novel Coronavirus (2019-nCoV) Triplex RT-qPCR Detection Kit

CATALOG NUMBER & SIZE

CD302-02: 100 tests / kit

INTENDED USE

This product is intended for the detection of 2019-Novel Coronavirus (2019-nCoV).

The detection result of this product is only for clinical reference, and it should not be used as the only evidence for clinical diagnosis and treatment.

PRINCIPLE OF DETECTION

This product is a multiplex fluorescent probe-based Taqman® RT-qPCR assay system. The Taqman fluorescent probe is a specific oligonucleotide based on a reporter-quencher mechanism. For each probe, the 5'-end is labeled with a fluorophore, while the 3'-end was labeled with a quencher. When the probe is intact, the fluorescence emitted by the fluorophore is absorbed by the quencher, and no fluorescent signal is detected. However, during amplification of the template, the probe will be degraded due to the 5'-3' exonuclease activity of Taq DNA polymerase, and the fluorescent reporter and the quencher are cleaved and separated, then a fluorescent signal can be detected. The generation of each molecular amplicon is accompanied by the generation of a fluorescent signal. Real-time monitoring of the entire PCR process can be assessed by monitoring the accumulation of fluorescent signals.

This product provides triplex-detections in a single tube, including two independent genes of 2019-nCoV and an internal control which targets the human RNase P (RNP) gene to assess specimen quality. Specific primers and probes were designed for the detection of conserved region of 2019-nCoV's ORF1ab gene (RdRP region) and N gene, respectively, avoiding non-specific interference of SARS2003 and BatSARS-like virus strains. Internal control (RNase P gene) provides a nucleic acid extraction procedural control and a secondary negative control. Positive control (2019-nCoV-pseudovirus) provides a nucleic acid extraction and a reverse transcription control to validate the entire procedure and reagent integrity.

PRODUCT CONTENTS

Components	Amount	Ingredient	Cap Color
Detection Buffer	900 µL × 3 tubes	Buffer, dNTPs, Primers, Probes.	●
Enzyme Mix	400 µL × 1 tube	RNase Inhibitor, UDG, Reverse Transcriptase, Taq DNA polymerase.	●
Positive Control	250 µL × 1 tube	RNA pseudovirus containing target gene.	●
Negative Control	250 µL × 1 tube	DEPC-Treated Water.	●

Note:

- Do not mix the components from different batches for detection.
- Additional Materials Required: Nucleic acid extraction reagents.
- Nucleic acid extraction must be performed simultaneously with the Positive control (2019-nCoV-pseudovirus) and Negative Control (DEPC-Treated Water) for monitoring the entire procedure to reduce false negative or false positive rates.

STORAGE & SHELF LIFE

All reagents should be stored at -30°C~-15°C with protection from light. The reagents are stable for 6 months when stored at the recommended condition.

The expiration date will not change if the kit is opened and stored at the recommended condition.

The expiration date will not change if the kit is transported with ice-packs for 4 days and/or treated with 10 freeze-thaw cycles.

INSTRUMENTS

Real-time PCR instrument with FAM, TEXAS RED/ROX and HEX/VIC channels, such as ABI7500, ABI Q3, ABI Q6, Roche LightCycler480, Bio-Rad CFX96.

SAMPLING & HANDLING

- Suitable specimen type: upper respiratory specimen (including nasal swabs, nasopharyngeal swabs / aspirates / washes, and sputum) and lower respiratory specimen (including respiratory aspirates, bronchial washes, bronchoalveolar lavage fluids, and lung biopsy specimens).
- For detailed methods of specimen collection, please refer to the protocol in the "Microbiology Specimen Collection Manual".
- The collected specimen should be used for detection within the same day. Otherwise, please store the specimen as follows:
Store at 2°C - 8°C for no more than 24 hours;
Store at < -20°C for no more than 10 days;
Store at < -70°C for long-term, avoiding repeated freeze-thaw cycles.
- The specimen should be transported using sealed foam box with dry ice.

PROTOCOL

1. Specimen Preparation (Specimen Preparation Area)

The samples should be extracted according to the corresponding requirements and procedures of viral RNA extraction kits. Each nucleic acid extraction procedure must be performed simultaneously with one Positive control (add 5 µL, dilute with sterile saline solutions to desired volume) and one Negative Control (add 5 µL, dilute with sterile saline solutions to desired volume). The extracted RNA can be directly used for detection. If the extracted RNA is not used for detection immediately, please store the RNA at below -70°C, avoiding repeated freeze-thaw.

2. Reagent Preparation (PCR Reagent Preparation Area)

Thaw the required reagents, mix by shaking, and centrifuge briefly before use.

Prepare the mixture in a RNase-free centrifuge tube as follows^[1]:

Components	Volume (µL Per Reaction)
Detection Buffer	26
Enzyme Mix	4
Total Volume	30

[1] Calculate the number of reaction tubes (sample number + positive control + negative control). It is recommended to set both negative and positive controls for each test.

Mix the above mixture thoroughly, and make aliquots of 30 µL into different PCR reaction tubes. Then, move to the Specimen Preparation Area.

3. Template Addition (Specimen Preparation Area)

Add 20 µL of extracted Negative Control products, 20 µL of extracted Positive Control products, and 20 µL of extracted RNA from specimen to different PCR reaction tubes which contained 30 µL of PCR mix. The total volume is 50 µL. Cap the reaction tubes tightly, centrifuge them at low speed. Then, move to the Detection Area.

4. RT-PCR Amplification (Detection Area)

Put the reaction tubes on a PCR instrument, setup and run the following cycling protocol:

Step 1	Reverse Transcription	Cycles: 1	50°C	15 min
Step 2	Pre-denaturation	Cycles: 1	95°C	30 sec
Step 3	PCR Cycles	Cycles: 45	95°C	10 sec
			58°C (Read)	30 sec

Settings of detection fluorescence: ORF1ab gene (FAM), N gene (TEXAS RED / ROX), Internal Control (HEX/VIC). Please set the internal reference parameter of fluorescence of the instrument to "None". For example: for ABI series instruments, please set "Passive Reference" to "None".

5. Data Analysis (refer to Instrument User Manual)

Take ABI7500 as an example: after the qPCR reaction, the results were saved automatically. According to the analyzed image, please adjust the Start value, End value, and Threshold value of the Baseline (Start value: 3 ~ 15; End value: 5 ~ 20; Threshold value could be set in the Log window, and the threshold line should be in the exponential phase of the amplification curve; the amplification curve of the negative control should be straight or below the threshold line).

Click "Analysis" to obtain the analysis result automatically, and read the detection result in the "Report" window.

QUALITY CONTROL

	Channel	Normal Ct
Negative Control	FAM	No Ct or Ct > 38
	TEXAS RED/ROX	No Ct or Ct > 38
	HEX/VIC	No Ct or Ct > 38
Positive Control	FAM	Ct ≤ 33
	TEXAS RED/ROX	Ct ≤ 33
	HEX/VIC	Ct ≤ 33

The result is *valid* if ALL the above criteria is met. Otherwise, the result is *invalid*.

INTERPRETING TEST RESULTS

If the criteria of QUALITY CONTROL is met, analysis the data of sample as follows:

*1. If the Ct value of HEX/VIC (Internal Control) channel is >33, it may indicate that the detected specimen contains lower concentration of cells, extracted nucleic acid was degraded or certain inhibitors were present in the reaction.

*2. If the Ct value of HEX/VIC channel is ≤ 33, analyzing the results according to the following table:

Interpreting Test Results		FAM (ORF1ab gene)	
		Ct ≤ 38	No Ct or Ct > 38
TEXAS RED/ROX (N gene)	Ct ≤ 38	2019-nCoV Positive	Test Again, and if repeated: 2019-nCoV Negative ; If not: suspicious*
	No Ct or Ct > 38	Test Again, and if repeated: 2019-nCoV Positive ; If not: suspicious*	2019-nCoV Negative

*No requirement for HEX/VIC channel test results, if the sample is extracted from virus culture.

*For suspicious samples, it is recommended to re-collect specimen or change the collection location, then test the specimen again.

ASSAY LIMITATIONS

1. The detection result of this product is only for clinical reference, and it should not be used as the only evidence for clinical diagnosis and treatment. The clinical management of patients should be considered in combination with their symptoms/signs, history, other laboratory tests and treatment responses. The detection results should not be directly used as the evidence for clinical diagnosis, and are only for the reference of clinicians.

2. The detection result can be affected by operations, including specimen collection, storage and transportation. False negative result may occur if there is any mistakes in the operation. Cross contamination during specimen treatment may lead to false positive result.

3. The detected target sequences of this products are the conservative region of 2019-nCoV's ORF1ab gene and N gene. However, target sequence variations may lead to false negative result.

PERFORMANCE SPECIFICATIONS

1. Detection limitation: 200 copies/mL.

2. Precision: using precision reference CV1 and CV2 for within-batch and between-batch detection, the coefficient of variation (CV) of their Ct values is ≤5.0%.

3. Conformity rate of Negative Control: 100%

4. Conformity rate of Positive Control: 100%

5. Specificity: No non-specific interference of Influenza A Virus (H1N1, H3N2, H7N9, H5N1), Influenza B Virus (Yamagata, Victoria), Respiratory Syncytial Virus (type B), Respiratory Adenovirus (type 3, type 7), Haemophilus influenzae, Staphylococcus aureus, Streptococcus Pneumoniae, etc.

ATTENTIONS

1. Please read this manual carefully before beginning the experiment, and strictly follow the instructions.

2. This product should be only used by trained labor personnel in safety-protected laboratories and wear appropriate protective equipments.

3. This product should be protected from light. Please use sterile, DNase-free, and RNase-free tubes and tips during the detection.

4. The tested specimen of this product is regarded as infectious material.

The operation and treatment should meet the requirements of the local regulations and laws.

CONTACT

Manufacturer: Nanjing Vazyme Medical Technology Co., LTD.

Address: Building C1-2, Red Maple Park of Technological Industry, Nanjing, China

Tel: +86 25 8436 5701

Customer Service Provider: Nanjing Vazyme Medical Technology Co., LTD.

Address: Building C1-2, Red Maple Park of Technological Industry, Nanjing, China

Tel: +86 25 8436 5701

REFERENCE

Hui DS, I Azhar E, et. al. (2020). The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health-The latest 2019 novel coronavirus outbreak in Wuhan, China. *International Journal of Infectious Diseases*, 91, 264-266.




DATE OF APPROVAL AND MODIFICATION OF INSTRUCTION




February 28th , 2020




DATE OF MANUFACTURE AND EXPIRATION


See packaging.

Symbols

	Authorized Representative
	For in vitro diagnostic use only
	Store between -30°C~-15°C

	Tests per kit
	Catalog #
	Lot Number

	Manufacturer
	Expire Date
	Consult instructions for use

 Nanjing Vazyme Medical Technology Co., LTD.
 Building C1-2, Red Maple Park of Technological
 Industry, Nanjing, China
www.vazymemedical.com





Polgen Sp. z o.o. Sp.K.

92-516 Lodz, Puskina Str. 80, Poland